Protara Therapeutics (TARA) Cash from Investing Activities (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Cash from Investing Activities data on file, last reported at -$14.7 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 74.77% year-over-year to -$14.7 million in Q1 2026; TTM through Mar 2026 was -$95.9 million, a 53.87% decrease from a year earlier, with the FY2025 full-year figure at -$139.5 million, down 828.22% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$14.7 million, up from -$26.9 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for TARA reached as high as $23.1 million in Q1 2024 and fell as low as -$58.4 million in Q1 2025.
• Historically, Cash from Investing Activities has averaged -$3.9 million across 5 years, with a median of $2.9 million in 2024.
• Across the five-year window, Cash from Investing Activities surged 17701.87% in 2022 and slumped 1720.48% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$18.3 million in 2022, then surged by 179.14% to $14.5 million in 2023, then soared by 54.98% to $22.5 million in 2024, then plunged by 219.59% to -$26.9 million in 2025, then surged by 45.29% to -$14.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$14.7 million in Q1 2026, -$26.9 million in Q4 2025, and -$6.5 million in Q3 2025.